Literature DB >> 3606938

Cyclosporin-erythromycin interaction in normal subjects.

D J Freeman, R Martell, S G Carruthers, D Heinrichs, P A Keown, C R Stiller.   

Abstract

We studied the pharmacokinetic interaction between cyclosporin (CYA) and erythromycin in normal subjects. Plasma CYA concentrations were measured by high performance liquid chromatography (h.p.l.c.) and radioimmunoassay (RIA) and estimates of metabolite formation were obtained from inter-assay differences between these measurements. Erythromycin significantly increased the maximum concentration and the area under concentration-time curve. Time to maximum concentration and apparent oral clearance of CYA were significantly decreased. The half-life, however, was not altered. Significant reductions in the proportion of apparent metabolite were observed at times of maximum CYA concentrations but not at later time periods (12 and 24 h). The mechanism of the drug interaction appears to be decreased hepatic first-pass metabolism but an effect on CYA absorption cannot be excluded. These results on normal subjects confirm that patients administered CYA and erythromycin risk CYA toxicity. However, the risk can be reduced by dose reduction based on more frequent CYA monitoring or by using a different antibiotic.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606938      PMCID: PMC1386176     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Possible interaction between cyclosporine and erythromycin.

Authors:  D E Kohan
Journal:  N Engl J Med       Date:  1986-02-13       Impact factor: 91.245

2.  The effects of erythromycin in patients treated with cyclosporine.

Authors:  R Martell; D Heinrichs; C R Stiller; M Jenner; P A Keown; J Dupre
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

3.  Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay.

Authors:  S G Carruthers; D J Freeman; J C Koegler; W Howson; P A Keown; A Laupacis; C R Stiller
Journal:  Clin Chem       Date:  1983-01       Impact factor: 8.327

4.  Cyclosporine for treatment of early type I diabetes: preliminary results.

Authors:  C R Stiller; A Laupacis; J Dupre; M R Jenner; P A Keown; W Rodger; B M Wolfe
Journal:  N Engl J Med       Date:  1983-05-19       Impact factor: 91.245

5.  Effect of erythromycin on cyclosporine levels.

Authors:  R J Ptachcinski; B J Carpenter; G J Burckart; R Venkataramanan; J T Rosenthal
Journal:  N Engl J Med       Date:  1985-11-28       Impact factor: 91.245

6.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

7.  Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites.

Authors:  D J Freeman; A Laupacis; P A Keown; C R Stiller; S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

8.  Effects of erythromycin on hepatic drug-metabolizing enzymes in humans.

Authors:  D Larrey; C Funck-Brentano; P Breil; J Vitaux; C Theodore; G Babany; D Pessayre
Journal:  Biochem Pharmacol       Date:  1983-03-15       Impact factor: 5.858

  8 in total
  19 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

3.  The effects of spiramycin on plasma cyclosporin A concentrations in heart transplant patients.

Authors:  R Guillemain; E Billaud; G Dreyfus; C Amrein; M Kitzis; V A Jebara; C Kreft-Jais
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

5.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

6.  Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study.

Authors:  Xiaochun Wu; Qing Li; Huawen Xin; Airong Yu; Mingyuan Zhong
Journal:  Eur J Clin Pharmacol       Date:  2005-08-26       Impact factor: 2.953

7.  Lack of effect of spiramycin on cyclosporin pharmacokinetics.

Authors:  L Vernillet; P Bertault-Peres; Y Berland; J Barradas; A Durand; M Olmer
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

8.  The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig.

Authors:  D J Freeman; D R Grant; S G Carruthers
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

9.  Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers.

Authors:  T D Lindstrom; B R Hanssen; S A Wrighton
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 10.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.